Treatment of prostate cancer (PC) by androgen suppression promotes the emergence of aggressive variants that are androgen receptor (AR) independent. Here we identify the transcription factor ONECUT2 (OC2) as a master regulator of AR networks in metastatic castration-resistant prostate cancer (mCRPC). OC2 acts as a survival factor in mCRPC models, suppresses the AR transcriptional program by direct regulation of AR target genes and the AR licensing factor FOXA1, and activates genes associated with neural differentiation and progression to lethal disease. OC2 appears active in a substantial subset of human prostate adenocarcinoma and neuroendocrine tumors. Inhibition of OC2 by a newly identified small molecule suppresses metastasis in mice. These findings suggest that OC2 displaces AR-dependent growth and survival mechanisms in many cases where AR remains expressed, but where its activity is bypassed. OC2 is also a potential drug target in the metastatic phase of aggressive PC.
A ggressive PC variants are poorly understood and associated with rapid treatment resistance, metastasis, and death 1 . Although the precise clinical, pathologic, and molecular features of these variants continue to be refined, the AR, considered to be the primary oncoprotein in PC and mCRPC, is often heterogeneously expressed, even under conditions of AR gene amplification 2 .
In prostate tumors expressing AR, resistance to hormonal therapies may occur through clonal selection, adaptation to decreased androgen, or intracrine mechanisms 3 . Although many mCRPC appear to rely on AR activity, even when the androgen axis is pharmacologically suppressed, recent studies suggest that alternative transcriptional pathways emerge in lethal disease 4 . For example, in contrast to primary PC, in one population of patients with mCRPC, AR gene expression signatures are inversely correlated with signatures of cell proliferation 5 . AR also exerts a tumor and metastasis suppressor function in basal-like PC 6 . These observations show that disease progression is compatible with reduced AR activity.
Here we describe the results of experimental testing of a bioinformatics model that identified the atypical homeobox protein ONECUT2 (HNF6β /OC-2/OC2 hereafter, OC2) as a highly active transcription factor (TF) in mCRPC. OC2 and the paralog ONECUT1 play a role in liver, pancreatic, and neuronal development [7] [8] [9] . A role for OC2 in cancer is not well defined, and studies of OC2 activity in PC are limited. One report identified OC2 mRNA in urine of patients with PC 10 and a PC risk-associated genetic variant, which modifies expression of the long noncoding RNA (lncRNA) PCAT1, was recently shown to be associated with OC2 activity 11 .
In this study we demonstrate that OC2 functions as a master regulator and survival factor that controls transcriptional networks that emerge in aggressive PC variants. We further demonstrate that OC2 can be targeted with a small molecule that inhibits mCRPC metastasis.
Results
Computational modeling predicts OC2 as a key transcriptional regulator in mCRPC. We recently described a resource developed from the assembly of 38 transcriptome datasets from 2,115 PC cases, including 260 samples of mCRPC 12 . This dataset was used as a discovery (DISC) cohort to identify key TFs in mCRPC using master regulator analysis (see Methods). Out of 402 TFs included in the model, we identified 31 TFs as significantly active in mCRPC compared with high-grade primary tumors (Fig. 1a) , while 7 TFs were calculated to be significantly downregulated ( Supplementary  Fig. 1a ). The ten most active TFs identified in this procedure are ranked in Fig. 1b . EZH2 was ranked first, with the largest fraction of target genes showing significant correlation with EZH2 gene expression. Next, we constructed a network model that considers the correlation between the expression of the ten TFs and expression of their target genes, as well as pairwise interactions between ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axis E2F3  FOXM1  EZH2  MTF2  AR  SMARCA4  POU5F1  E2F7  PAX5  ONECUT2  E2F1  E2F2  NKX2-1  DNAJC2  TLX2  HNF1A  JUND  POU3F3  POU2F1  ONECUT1  PHF8  NFYA  GFI1B  SP1  ZIC3  GCM1  E2F5  JARID2  NR5A1 ERG SUZ12 , a statistical measure of TF activity (Benign, n = 794; GS < 7, n = 328; GS = 7, n = 530; GS > 7, n = 203; mCRPC, n = 260). b, Ranking of the ten most active TFs (from a) in mCRPC from the DISC cohort. c, A network model describing activity and association of highly active TFs in mCRPC. TFs are identified as nodes. Node size represents activity. Node color represents proportion of patients where the TF is up or downregulated, or unchanged. Edges represent degree of interaction. Edge thickness represents concordance in RNA expression. d, The bar plot (top) displays summary of TF activation across disease categories. The heat map (bottom) shows activation of individual TFs across disease categories. e,f, Representative images (e) and quantitation (f) of OC2 expression (red) in benign (n = 79), Gleason grade 3 (G3, n = 82), and Gleason grade 4 (G4, n = 66) PC tissues. Tissue sections are stained using a fluorescent antibody detection system and nuclei visualized with DAPI (blue). Scale bar, 40 μ m. The boxes show the 25th-75th percentile range, and the center line is the median. Whiskers show 1.5 times the interquartile range (IQR) from the 25th or 75th percentile values. P values were obtained from Wilcoxon two-tailed rank-sum test. g, Immunoblot showing endogenous OC2 levels in prostate cell lines. Representative blots from two independent experiments. Full-length blots are presented in Supplementary Fig. 8 . h, Inferred activity of OC2 in PCS1-3 subtypes 12 plotted by disease category. Upper and lower panels show inducible and repressive activity of OC2, respectively. Right panel shows overall OC2 activity in GS > 7 and mCRPC tumors. Red, PCS1; green, PCS2; blue, PCS3. The boxes show the 25th-75th percentile range and the center mark is the median. Whiskers show 1.5 times IQR from the 25th or 75th percentile values. Data points beyond the whiskers are displayed using dots. (GS < 7 and PCS1, n = 28; GS < 7 and PCS2, n = 158; GS < 7 and PCS3, n = 142; GS = 7 and PCS1, n = 98; GS = 7 and PCS2, n = 201; GS = 7 and PCS3, n = 231; GS > 7 and PCS1, n = 79; GS > 7 and PCS2, n = 52; GS > 7 and PCS3, n = 72; mCRPC and PCS1, n = 172; mCRPC and PCS2, n = 17; mCRPC and PCS3, n = 71; GS > 7 or mCRPC and PCS1, n = 251; GS > 7 or mCRPC and PCS2, n = 69; GS > 7 or mCRPC and PCS3, n = 143). them. The model (Fig. 1c) has a number of interesting features: (i) it contains TFs known to be active in PC (EZH2, AR, FOXM1, and E2F3); (ii) the predicted activity of OC2 is comparable with that of EZH2, a known driver of mCRPC 13 ( Fig. 1b,c) ; (iii) OC2 is predicted to be networked with other key TFs, such as POU5F1 (Oct-4), PAX5, AR, and EZH2; and (iv) predicted OC2 activity is greater than AR activity. Overall activity of this network is relatively high in mCRPC compared with other disease categories (Fig. 1d , n = 1,321). Principal component analysis indicated that the network model has high discriminatory accuracy in distinguishing mCRPC from localized disease ( Supplementary Fig. 1b) . Quantitative analysis of OC2 immunostaining intensity, using a PC tissue microarray (TMA) containing benign prostate, low-grade (Gleason pattern 3, G3) and high-grade (G4) cancers, showed that nuclear and cytoplasmic OC2 protein levels were increased in aggressive disease (Fig. 1e,f) . Consistent with this, in the DISC cohort (n = 2,115), OC2 mRNA expression increased gradually from benign prostate tissue to mCRPC, and this pattern was distinct from AR expression, where increased expression was only observed in mCRPC ( Supplementary Fig.1c ).
Evidence of OC2 activity in mCRPC. OC2 protein is expressed in metastatic, castration-resistant 22Rv1, C4-2, and PC3 PC cell lines, in weakly metastatic, androgen-dependent LNCaP PC cells, and at detectable but substantially lower levels in moderately metastatic, castration-resistant DU145 PC cells (Fig. 1g) . Nontumorigenic RWPE-1 PC cells are negative. To study the role of OC2 in aggressive PC, we performed gene expression profiling using 22Rv1 and LNCaP cell lines. OC2 was enforced in LNCaP and 22Rv1 or silenced in 22Rv1 ( Supplementary Fig. 1d ). OC2-induced and OC2-repressed genes were identified with false discovery rate (FDR) < 0.05 and fold-change ≥ 2 ( Supplementary Fig. 1e ). OC2-induced genes were enriched in pathways related to cell motion, neuronal differentiation, and mesenchymal cell differentiation ( Supplementary  Fig. 1f ), whereas OC2-repressed genes were enriched in pathways corresponding to AR activity, β 3-and β 1-integrin cell surface interactions, and syndecan-4-mediated signaling ( Supplementary  Fig. 1g ). These data suggest that OC2 interacts with the AR transcriptional program. To explore this further, OC2-regulated genes were compiled into an OC2 activity gene signature (Supplementary  Table 1 ), which we used to infer OC2 activity in transcriptome datasets. The signature was used to calculate a z score 14 of OC2-induced and OC2-repressed activity in each tumor in the DISC cohort. Hierarchical clustering of cases in the DISC cohort showed that OC2 activation is positively correlated with signatures reflecting activation of rat sarcoma viral oncogene homolog (RAS), derepression of genes regulated by polycomb repression complexes, epithelial-mesenchymal transition, proneural, and aggressive PC and is negatively correlated with the AR signature ( Supplementary  Fig. 1h ). OC2 activity was also assessed using the PCS1-3 classification scheme 12 ( Fig. 1h ). Among these three subtypes, the PCS1 luminal subtype is consistently more aggressive, and PCS1 luminal and PCS3 basal subtypes are over-represented in mCRPC in comparison with PCS2 12 . OC2 activity was highest in PCS1 and PCS3 tumors across the disease course, including Gleason sum score > 7 and mCRPC tumors. These data suggest that OC2 functions in luminal as well as basal PC.
The above results imply that OC2 can operate under conditions of suppressed AR activity. Consistent with this, in mCRPC tumors from the DISC cohort (n = 260), AR activity was significantly decreased in tumors with high OC2 expression ( Supplementary  Fig. 1i ). Similarly, OC2 expression was induced in a model where long-term androgen deprivation resulted in castration resistance 15 and was highly elevated in the KRas-active/Pten-null transgenic model 16 , where AR expression is suppressed ( Supplementary  Fig. 1j ). By contrast, in the LNCaP-abl mCRPC model, which is characterized by hyperactive AR, OC2 expression was suppressed ( Supplementary Fig. 1j ). Using a different approach, OC2 expression in the entire DISC cohort was positively correlated with expression of AR-repressed gene activity 17 ( Supplementary Fig. 1k ). Taken together, these results suggest that OC2 is active when AR activity is repressed.
OC2 negatively regulates the AR and its transcriptional program. Considering that OC2 expression and inferred activity correlate inversely with AR activity, we measured AR and OC2 levels in individual nuclei in six cases of high-grade PC by multiplex immunofluorescence (IF) microscopy using anti-OC2 and anti-AR antibodies. Hierarchical clustering indicates that nuclei can be separated into two groups: high OC2/low AR and low OC2/high AR (Fig. 2a) . Next we performed the same analysis on 35 cases of high-grade PC. OC2 expression was detected in the cytoplasm and nucleus of AR-positive and AR-negative cancer cells (Fig. 2b) . Nuclear OC2 and AR expression was inversely correlated in cells expressing both OC2 and AR (Fig. 2c) .
The above evidence suggests that OC2 suppresses AR activity. Consistent with this, when OC2 expression was enforced in LNCaP, 22Rv1, and C4-2 cells, AR mRNA and protein were downregulated, including AR-V7, a common truncated AR splice variant 18 ( Fig. 2d and Supplementary Fig. 2a ). The AR-regulated genes KLK3 (PSA), KLK2, and EHF were repressed by OC2 ( Fig. 2e and Supplementary  Fig. 2b ). To determine whether OC2 directly regulates the AR transcriptional program or whether the effect of OC2 is a consequence of AR downregulation, we performed OC2 chromatin immunoprecipitation and sequencing (ChIP-seq) using the 22Rv1 cell line (Fig. 3a) , which expresses relatively high levels of OC2. In an analysis of two experimental replicates, 8,131 OC2 peaks were observed, of which 67% were in promoters, 10% in intergenic regions distal to transcriptional start sites, and the remainder in untranslated regions, exons, introns, and immediately downstream of gene bodies ( Supplementary Fig. 3a) . The consensus motif with highest enrichment of solo OC2-binding sites was a ZBTB33-like (Kaiso) motif (E value = 1.6 × 10 -540 ), and the second-ranked motif was a ONECUT-like motif (E value = 9.8 × 10 −207 ) (Fig. 3b) . Using the OC2-regulated transcriptome, as defined in LNCaP and 22Rv1 from enforced OC2 expression and OC2 depletion, endogenous OC2 bound to the promoters of 25% of the perturbed genes (1,791 out of 7,095). Endogenous OC2 bound to promoter regions of 474 genes that were positively regulated by enforced OC2 in 22Rv1 cells, and to the promoters of 594 genes that were negatively regulated. These results suggest that OC2 directly activates as well as suppresses genes where it binds to promoter regions.
To determine whether OC2 and AR share common regulatory targets, we compared these OC2 ChIP-seq data with published AR ChIP-seq data obtained from 22Rv1 cells 19 . The AR consensus binding motif was the most common motif observed for AR, followed by the FOXA1 consensus motif (Supplementary Fig. 3b ). We identified 2,151 peaks (26% of OC2 peaks) that were significantly bound by both OC2 and AR (Fig. 3a) ; however, a majority of the OC2 peaks did not overlap with AR-binding regions, suggesting that OC2 can function independently of the AR. OC2-AR shared sites and OC2 solo sites were predominantly in transcriptionally active regions, on the basis of colocalization with H3K27ac. This pattern was distinct from AR-enriched/OC2-depleted regions, which were largely distal to transcription start sites but colocalized with well-positioned H3K4me1 enhancer marks ( Fig. 3a and Supplementary Fig. 3c ). OC2 potentially regulates over 500 TF genes on the basis of OC2 binding to gene promoters ( Supplementary Fig. 3d ), consistent with the master regulator network model (Fig. 1c) .
Of the 2,151 regions with shared OC2 and AR binding peaks, 809 were situated within gene promoters. To address the functional relationship between OC2 and AR at these shared sites, we analyzed the promoters of 101 genes from an androgen response hallmark gene signature 20 . OC2 bound to 48 of these genes (48/101, P = 2.0 × 10
−11
). This represents a relative enrichment of 3.2-fold over the expected ratio of 14.8% when comparing the total of 809 shared peaks out of a totoal of 5,448 OC2 promoter peaks (P = 7.4 × 10
−17
). Of these 48 genes, 41 contained shared OC2-AR sites in the promoters (85%), on the basis of a comparison with AR-binding sites in the ReMap database 21 , which incorporates multiple datasets from a wide range of cell types including five datasets from three PC cell lines (VCaP, LNCaP and LNCaP-abl). We next performed gene set enrichment analysis (GSEA) with the 48-gene set of OC2-AR targets in the androgen response hallmark signature using the transcriptome datasets obtained from OC2 overexpression or silencing. Enforced OC2 expression significantly repressed the majority of the 48 OC2-AR target genes in both 22Rv1 and LNCaP (Fig. 3c) , whereas OC2 silencing exhibited modest de-repression of these genes ( Supplementary Fig. 3e ). The inverse relationship between OC2 and AR gene expression was confirmed in another AR-regulated gene set from CRPC tissues 4 . OC2 ChIP-seq peaks were noted in promoter regions of 323 out of 1,367 genes in this gene set, with an enrichment score similar to the previous gene set ( Supplementary Fig. 3f ). ChIP-seq showed OC2 binding to the AR promoter and to an AR intron (not shown); this was confirmed by ChIP-qPCR ( Supplementary Fig. 3g ), consistent with OC2 acting as a direct repressor of AR gene expression. Taken together, these findings indicate that OC2 and AR act in functional opposition at promoter sites throughout the genome.
Prostate-specific antigen (PSA, also known as KLK3) is a classic regulatory target of AR 22 . We observed a strong OC2 ChIP-seq peak in the well-characterized AREIII 23 KLK3 enhancer region (Fig. 3d) . This peak overlapped with AR binding. In the presence of dihydrotestosterone (DHT), ectopic OC2 suppressed endogenous PSA gene expression and activity of a PSA enhancer/luciferase construct (Fig. 3e,f) . Similar to PSA, the androgen-responsive genes EGFR, NAT1, and BASP1 also showed OC2 and AR binding in the promoters (Fig. 3g) . In the presence of DHT, EGFR, NAT1, . d, AR and FOXA1 protein in PC cell lines after enforced expression of OC2. Representative blots from two independent experiments. Full-length blots are presented in Supplementary Fig. 8 . e, PSA mRNA expression after enforced expression of OC2. The mean + s.e.m. from three to four independent experiments is shown. Unpaired two-tailed Student's t-test; for 22Rv1, and BASP1 mRNA were lower in the ectopic OC2 condition than in controls (Fig. 3h ). OC2 and AR cobinding to some of these regions was confirmed by ChIP-qPCR ( Supplementary Fig. 3h ), and formation of a complex between endogenous OC2 and AR was demonstrated by coimmunoprecipitation ( Supplementary Fig. 3i ). These results are consistent with a direct antagonistic effect of OC2 on a subset of the AR-regulated transcriptome.
OC2 activates an mCRPC transcriptional program. The single enriched motif in the OC2-AR shared regions was a FOX-like motif (E value = 2.7 × 10 −143
, Fig. 3i ). Enrichment of this motif only occurred in regions with OC2 and AR binding and not at OC2 solo binding sites (Fig. 3b ). FOXA1 is a pioneer factor involved in positioning AR on chromatin 24 . These results suggest that a subset of genes is jointly regulated by AR, FOXA1, and OC2. Because we observed suppression of AR by OC2, we examined whether OC2 might also inhibit FOXA1. Endogenous OC2 bound the FOXA1 promoter and gene body (Fig. 3j) . Enforced OC2-repressed FOXA1 mRNA and protein expression in LNCaP, 22Rv1, and C4-2 cells (Figs. 2d and 3k) .
A recent report identified FOXA1 as an inhibitor of neuroendocrine (NE) differentiation that is lost with progression to mCRPC 25 . The observation that OC2 represses AR and FOXA1 suggests that OC2 may play a role in the emergence of NE properties in CRPC. Consistent with this, NE differentiation, assessed using a published signature 26 , in mCRPC tumors in the DISC cohort was elevated in tumors with high OC2 (Fig. 4a ). OC2 depletion in 22Rv1 cells resulted in attenuation of NE differentiation, evaluated using the same signature ( Supplementary Fig. 4a ). OC2 expression is significantly increased in human NE-CRPC in comparison with adenocarcinoma (Adeno)-CRPC 26 ( Fig. 4b ). We noted relatively high OC2 expression in cell lines of neural or NE derivation in the 1,063 cancer cell lines of the Cancer Cell Line Encyclopedia (CCLE) 27 ( Supplementary Fig. 4b ). To quantify this observation, we applied running sum statistics to the CCLE dataset. We obtained a positive correlation between OC2 levels and cell lines with a neural phenotype, as designated by CCLE [27] [28] [29] [30] (Fig. 4c ). Synaptophysin (SYP) is a marker commonly used in clinical practice to identify NE differentiation in CRPC 31 . OC2 protein was detected in mCRPC specimens (n = 34) (Fig. 4d) . In these cases, nuclear OC2 was seen in AR-positive cells ( Supplementary Fig. 4c ).
However, the OC2 nuclear to cytoplasmic ratio was higher in AR-negative/SYP-positive tumors and AR-negative/SYP-negative tumors than in AR-positive/SYP-negative tumors 32 ( Fig. 4e ). In addition, in patient-derived xenografts from the LuCaP xenograft compendium 33 (n = 38), the OC2 nuclear to cytoplasmic ratio was higher in SYP-positive than in SYP-negative tumors, and was further increased in castration-resistant (CR)/SYP-positive xenografts (Fig. 4f,g and Supplementary Fig. 4d ). Consistent with this, enforced OC2-upregulated genes associated with NE differentiation (NSE, SYP, and CHGA) and with neuronal differentiation (NFASC, TUBB2B, LHX2, RET, CAV2, TGFB1, and MTSS1) ( Supplementary Fig. 4e ,f) and promoted neural morphological features ( Supplementary Fig. 4g ).
Loss of REST, a master repressor of neuronal differentiation, has been implicated in NE-CRPC 34 . The ONECUT2 promoter contains a conserved REST-binding site ( Supplementary Fig. 4h ), suggesting that REST is a direct OC2 repressor. Depletion of REST resulted in upregulation of OC2 mRNA levels in C4-2, LNCaP, and DU145 cells ( Fig. 4h and Supplementary Fig. 4i ). ChIP-qPCR demonstrated direct binding of REST at the ONECUT2 promoter (Fig. 4i ).
In the DISC cohort, we found an inverse correlation between OC2 and REST gene expression in mCRPC (n = 260, r = − 0.21), but not in benign (n = 673, r = − 0.08) or locally confined prostate tumors (n = 1,061, r = − 0.01) (Fig. 4j ). An inverse correlation (r = − 0.44) was also seen in a separate neuroendocrine PC (NEPC) cohort 26 ( Fig. 4k) . Consistent with this, REST mRNA expression dramatically declined and OC2 mRNA increased with transition from adenocarcinoma to NEPC in the LTL331 NE human xenograft transdifferentiation model 35 ( Supplementary Fig. 4j ). OC2 correlated inversely with REST mRNA expression in a cohort of human PC organoids 36 ( Supplementary Fig. 4k ). Notably, relative OC2 expression was highest and REST expression lowest in MSK-PCa4, an organoid line derived from a treatment-induced NE tumor. Similar to results described above from other datasets, the inferred OC2 activation signature correlated positively with an AR-repressed gene signature 17 , and OC2 activation correlated inversely with the hallmark AR gene signature in these organoids. These results indicate that REST is a disease-relevant repressor of OC2 expression.
The above results suggest that OC2 contributes to NE differentiation in mCRPC. Recently, the placental gene PEG10 was identified as a driver of NEPC in the LTL331 transdifferentiation . PEG10 is repressed by AR in PC cells, but during conditions of androgen suppression PEG10 is markedly upregulated. In the LTL331 model, OC2 expression increased in parallel with PEG10 during the transition from adenocarcinoma to NEPC (Fig. 4l) . Consistent with this finding, PEG10 and OC2 expression in NEPC 26 were highly correlated (Spearman's rho = 0.58, P < 0.001; not shown). OC2 binds to the PEG10 promoter (Fig. 4m) , and binding to this region was further confirmed by surface plasmon resonance (SPR) using a dsDNA probe corresponding to the OC2 motif in the PEG10 promoter (K D~1 nM, Supplementary Fig. 4l ). Enforced OC2 increased PEG10 mRNA levels (Fig. 4n) , indicating that OC2 is a direct upstream activator of PEG10 transcription. Collectively, these data position OC2 between REST and PEG10 during transdifferentiation of adenocarcinoma to NEPC. 
No. . i, Ratio of OC2 activation to AR activation in diagnostic prostate needle biopsies (M0-MN (n = 23) and M1-Poly (n = 52)). M1-Poly, patients with concurrent polymetastases (> 5 bone or extrapelvic lymph node metastases and/or visceral metastases) at the time of diagnostic biopsy. M0-NM, high-grade prostate tumor biopsies from patients that remained locally confined (no metastatic progression) with average follow-up of 56 months. The boxes show the 25th-75th percentile range, and the center line is the median. Whiskers show 1.5 times the IQR from the 25th or 75th percentile values. Data points beyond the whiskers are displayed using dots. Wilcoxon two-tailed rank-sum test, P = 0.043. j, Expression of OC2 mRNA in benign and high-risk primary prostate tumors from Wyatt et al. 37 . NHT, neoadjuvant hormone therapy. Targeting OC2 inhibits CRPC metastasis. To evaluate the function of OC2 in metastasis of CRPC, we depleted OC2 expression in multiple PC cell lines. OC2 silencing by lentiviral infection with two independent shRNA caused extensive apoptosis in LNCaP and C4-2 cells (Fig. 5a,b and Supplementary Fig. 5a ). This result was also seen with a third independent shRNA (data not shown). OC2 depletion using siRNA oligos caused similar effects in AR-negative PC3 cells (Supplementary Fig. 5b ). While OC2 loss caused cytotoxicity in 30% of 22Rv1 cells, which express high OC2 levels among the cell lines examined, the surviving OC2-deficient cells could be propagated and studied experimentally. Depletion of OC2 resulted in growth inhibition and impaired the ability of 22Rv1 cells to form colonies in soft agar (Fig. 5c,d) . Depletion of OC2 using siRNA oligos suppressed growth in 22Rv1, LNCaP, C4-2, and PC3 cells (Supplementary Fig. 5c ). To analyze the consequences of OC2 silencing in vivo, we subcutaneously engrafted 22Rv1 cells expressing control and OC2 shRNAs into immunodeficient nude mice and tracked tumor growth. Consistent with the in vitro results, OC2 depletion resulted in reduced tumor burden and tumor weight (Fig. 5e) . To evaluate the effect of OC2 depletion on metastasis, we injected luciferase-tagged 22Rv1/shOC2 or 22Rv1/shControl cells intracardially into SCID mice and monitored tumor growth by bioluminescence imaging. We observed reduction of metastatic growth at weeks 3-5 ( Fig. 5f ). Taken together, these findings demonstrate that OC2 depletion inhibits 22Rv1 growth and metastasis.
Consistent with the possibility of a role for OC2 in human PC metastasis, Kaplan-Meier analysis of two human PC cohorts showed that high expression of OC2 mRNA is associated with biochemical recurrence (Fig. 5g and Supplementary Fig. 5d ). In these cohorts, the tissues were obtained before treatment of localized PC, demonstrating that elevated OC2 expression can occur prior to androgen deprivation therapy (ADT) and confers risk of disease progression. To further investigate the relationship between OC2 activation and AR activation in patients at highest risk of developing CRPC, we compared transcriptome (RNA-seq) data from diagnostic prostate needle biopsies obtained from patients with high-grade nonmetastatic (M0-NM; metastasis-free with longterm follow-up) and metastatic (M1-Poly; patients presenting with concurrent polymetastases) disease. An inverse correlation between OC2 and AR activation was identified (Fig. 5h) , and tumors demonstrating high OC2 activity and low AR activity were significantly more abundant in the M1-Poly group (Fig. 5i) . OC2 mRNA was elevated in M1-Poly specimens in comparison with M0-NM specimens (Supplementary Fig. 5e ). In contrast, AR expression did not differ between these groups ( Supplementary  Fig. 5f ). In a separate cohort 37 , OC2 mRNA expression was also higher in high-risk primary prostate tumors from treatmentnaive patients compared with benign prostate tissue and tumors from patients treated with neoadjuvant ADT (Fig. 5j) . Among these patients, OC2 expression was highest overall in a hybrid Adeno-NE tumor and, in the neoadjuvant ADT group, in a NEPC transdifferentiated tumor.
These results suggest that OC2 might be a clinically relevant therapeutic target in the context of metastatic PC. To identify small-molecule inhibitors of OC2, we used structure-based drug design. We constructed a 3D model of the OC2-HOX domain and screened a chemical library consisting of 500,000 small molecules. One compound, CSRM617 (Supplementary Fig. 6a ), predicted to bind to OC2-HOX ( Supplementary Fig. 6b ), was biologically active in experimental tests and was selected for further study. CSRM617 inhibited cell growth and induced apoptosis in vitro in several PC cell lines that expressed moderate to high levels of OC2 ( Supplementary Fig. 6c-f ), phenocopying the effects observed when OC2 was depleted with shRNA or siRNA (Fig. 5a,b and Supplementary Fig. 5a-c) . Notably, OC2 RNA expression levels in the various cell lines correlated with the half-maximum inhibitory concentration (IC 50 ), indicating that cells with low OC2 expression were less responsive to treatment with the compound (Fig. 6a) . To evaluate the specificity of CSRM617 for genes regulated by OC2, we generated gene expression microarray data from 22Rv1 cells treated with the compound for 4, 6, and 16 hours. For this analysis, the OC2 target gene set was defined by OC2 binding to the gene promoters in the ChIP-seq dataset. GSEA showed significant perturbation of OC2 target genes at all three timepoints ( Fig. 6b and Supplementary Fig. 6g ). As described above, we identified PEG10 as a gene directly regulated by OC2 as a result of binding of the protein to the PEG10 promoter ( Fig. 4m and Supplementary Fig. 4l) . In response to CSRM617, PEG10 mRNA was downregulated in a time-dependent manner ( Supplementary  Fig. 6h ).
Next we used SPR to test whether CSRM617 binds directly to OC2. The OC2-HOX domain (amino acids 330-485) was expressed in a bacterial system, and it purified as a dimer in the absence of DNA (data not shown). As mentioned above, the dimeric protein bound with high affinity to a dsDNA probe corresponding to the experimentally determined OC2-binding motif in the PEG10 promoter ( Supplementary Fig. 4l ). CSRM617 bound to OC2 in a dose-dependent manner (K D = 7.43 μ M) (Fig. 6c) , demonstrating that the compound binds the OC2-HOX domain directly. Furthermore, in a competitive SPR assay, CSRM617 significantly inhibited OC2-HOX binding to immobilized DNA (Fig. 6d) .
To test the effect of CSRM617 in vivo, 22Rv1 cells were implanted subcutaneously in nude mice. Treatment with CSRM617 in small tumors (50 mm 3 ) showed significant reduction of tumor volume and weight (data not shown). To assess the efficacy of the compound in a setting that better mimics the clinical scenario, when tumors reached a size of 200 mm 3 , mice were randomized and treated daily with CSRM617 or vehicle control (2.5% DMSO in PBS) intraperitoneally at a dose of 50 mg kg
The treatment group showed significant reduction of tumor volume and weight (Fig. 6e) . CSRM617 did not affect body weight, suggesting the compound was well tolerated (Fig. 6f) . To determine whether CSRM617 is effective against PC metastases, luciferase-tagged 22Rv1 cells were injected intracardially in SCID mice and two days later the animals were randomized and treated daily (50 mg kg −1 ) with the compound or vehicle. CSRM617 elicited a significant reduction in the onset and growth of diffuse metastases (Fig. 6g) . To test for evidence of bioactivity of CSRM617 using an independent metric, PEG10 protein levels were quantitatively measured in tumors in both the experimental and control groups. PEG10 protein was significantly downregulated in tumors from mice treated with CSRM617 (Fig. 6h,i) . To assess the efficacy of the compound after metastases are already established, 22Rv1 luciferasetagged cells were injected intracardially in SCID mice. Mice that developed metastases ( Supplementary Fig. 6i ) were randomized (n = 11 per group) and treated daily (50 mg kg −1 ) with the compound or vehicle. CSRM617 elicited a significant reduction of diffuse metastases (Fig. 6j) . A representative result showing one control and one treated subject is shown in Fig. 6k . PEG10 protein levels were quantitatively measured in tumors in both the experimental and control groups. PEG10 protein was similarly downregulated in tumors from mice treated with CSRM617 (Fig. 6l,m) .
Discussion
This study identified OC2 as a central regulatory node in a subset of aggressive PC in which AR activity is relatively suppressed. OC2 emerged from an unbiased computational analysis that evaluated over 400 TFs in a large cohort of mCRPC. To our knowledge, this is the first master regulator TF network assembled specifically within the lethal phase of PC progression. We incorporated comprehensive TF-target relationships, available from public ChIP-seq and ChIPon-chip databases, and pairwise expression correlations between expression levels of TFs and their target genes. This procedure identified TFs known to play important roles in CRPC (AR, EZH2), less-studied TFs in CRPC (FOXM1, E2F3), and several TFs that are largely uncharacterized in CRPC (MTF2, E2F7, and PAX5). The outcome of the functional validation studies of OC2 suggests that the network we describe here is valuable in nominating other novel drivers of mCRPC. Interestingly, OC2 expression is significantly associated with poor clinical outcome in cancer types other than prostate, including breast, gastric, colon, clear cell renal, brain, and lung ( Supplementary Fig. 7a ), suggesting that it may play a wider role in aggressive cancers. Consistent with this concept, KEGG Pathway Enrichment of OC2 binding to chromatin using ChIPseq data identifies several other tumor types as potentially relevant (Supplementary Fig. 7b) . Notably, the most significant association with the OC2-AR shared sites was PC.
In PC, our findings suggest that OC2 operates as a genome-wide suppressor of AR activity, a survival factor, and a driver of a neural differentiation gene expression program within the context of adenocarcinoma. The AR is frequently referred to as the most significant PC oncoprotein, even in mCRPC, and is still the primary focus of novel drug design. AR activation under castrate conditions has been shown to arise from gene amplification 38 , androgen synthesis or retention within the tumor 3 , and collaboration with signal transduction pathways and other TFs 39 . Aggressive variants emerge following hormone therapy, and these tumors express variable levels of AR and, in some instances, NE features 40 . Histologically defined small-cell NEPC mostly arises before treatment and represents a less-frequent cause of mCRPC because of its low incidence ( < 5% of mCRPC) 38 . Transitions from adenocarcinoma to NEPC occur in cell and xenograft models 35, 41 . Our findings point to an important role for OC2 in the transition from AR-dependent adenocarcinoma toward AR-indifferent CRPC: (i) OC2 is a direct activator of PEG10, which was recently identified as a master regulator of the transition from adenocarcinoma to NEPC 35 ; (ii) ihe OC2 promoter is repressed by REST, a TF lost during progression to NEPC 34 ; (iii) OC2 inhibits expression of the AR pioneer factor, FOXA1 24 , which is downregulated during the transition from adenocarcinoma to NEPC 25 ; (iv) in a recently developed system for classifying PC 12 , OC2 activity was highest in the PCS3 subtype, which exhibits a relatively heightened NE differentiation program as evaluated by signature analysis, and PCS3 represents about onethird of mCRPCs evaluated, suggesting that activation of NE differentiation can occur without full progression to NEPC; and (v) the majority of OC2-binding regions on chromatin do not overlap with AR-binding sites, suggesting that OC2 can function independently of the AR. Consistent with this, OC2 depletion in AR-negative PC3 cells suppressed cell growth. Taken together, our findings suggest the existence of an mCRPC subtype, characterized by continued AR expression, reduced AR activity, and emergence of NE features, wherein OC2 operates as a survival factor.
Inhibition of the AR axis by OC2 suggests that tumor cells with increased OC2 expression could be selected following treatment with ADT. We present data demonstrating elevated OC2 mRNA expression in pretreatment diagnostic needle biopsy tissue of patients with de novo polymetastatic PC, suggesting the presence of OC2 activity in PC cells before therapy or metastatic dissemination. Since reports by others have associated OC2 with cell migration 42 , and our results link OC2 to tumor cell survival, emergence of OC2 activity in a primary tumor may be an important driver of PC metastasis before treatment. This hypothesis should be tested in future studies.
In summary, we have demonstrated that OC2 is a master regulator of lethal PC that may be an important therapeutic target in as many as one-third of mCRPC tumors. We have demonstrated that OC2 can be inhibited with a small molecule that suppresses human mCRPC metastasis in a xenograft model. Our study supports the conclusion that many lethal PCs, characterized histologically as adenocarcinoma, consist of cells with partial activation of an NE differentiation program in which OC2 plays a major role.
Online content
Any methods, additional references, Nature Research reporting summaries, source data, statements of data availability and associated accession codes are available at https://doi.org/10.1038/ s41591-018-0241-1.
The following antibodies were used for western blot: anti-GAPDH 14C10, rabbit, monoclonal (Cell Signaling, lot no. 4) (1:5,000); anti-β -Actin 12262 S, mouse, monoclonal (Cell Signaling, lot no. 1) (1:5,000); anti-FOXA1 ab23738, rabbit, polyclonal (Abcam, lot no. GR176970-1) (1:1,000); anti-Histone H3 3H1, rabbit, monoclonal (Cell Signaling, lot no. 1) (1:5,000); anti-Caspase-9 no. 9502, rabbit, polyclonal (Cell Signaling, lot no. 8) (1:1,000); anti-Caspase-3 31A1067, mouse, monoclonal (Novus Biologicals, lot no. AB022811A-08) (1:1,000); anti-PARP no. 9542, rabbit, polyclonal (Cell Signaling, lot no. 13) (1:1,000).
Lentiviral constructs.
Lentivirus were created by cotransfection of the Delta 8.9 packaging plasmid and the pCMV-VSVG plasmid (Addgene 8454) into Lenti-XTM-293T cells (Clontech) using Lipofectamine 2000 (Invitrogen). Medium was changed every 24 h, and the 48-and 72-h supernatants were filtered through a 0.45-μ m filter syringe for transduction of the recipient cells. The OC2 overexpression plasmid was obtained by cloning the full length OC2 cDNA (NM_004852) into the pLenti-C-Myc-DDK-IRES-Puro (Origene). For the knockdown of OC2, three validated shRNA clones (TRCN0000013443, TRCN0000013445, TRCN000235576) in the vector pLKO1 were purchased from Sigma. A nonmammalian shRNA control plasmid (TRC2-pLKO-puro non-target shRNA no. 1, Sigma) was used as a control. Cells were subsequently transduced in the presence of 5 μ g ml −1 of polybrene and selected on 5 μ g ml −1 puromycin to create the stable line. Gene expression microarrays. Total RNA was extracted using the RNeasy Kit (Qiagen) and hybridized to the Human U133plus2.0 Array Hybridization (Affymetrix) at the UCLA Clinical Microarray Core. The probe intensities were normalized using the quantile normalization method 43 . Gene expression datasets were deposited into the GEO database (GSE97549 and GSE97548). For the comparisons: (i) OC2 OE/Control in 22Rv1, (ii) OC2 OE/control in LNCaP, (iii) OC2 KD/control in 22Rv1, (iv) CSRM617 treated in 4 h per vehicle treated, (v) CSRM617 treated in 6 h per vehicle treated, and (vi) CSRM617 treated in 16 h per vehicle treated, we used the integrative statistical method 44 . Briefly, for each gene, an adjusted P value was computed by performing a two-tailed Student's t-test and log 2 median ratio test using the empirical distributions that were estimated by random permutations of the samples. The two sets of P values from the individual tests were combined into overall P values using Stouffer's method, and FDR was computed from the overall P values using Storey's method 45 . Finally, the differentially expressed genes were selected with the ones having FDR < 0.05 and fold-change > 2. We then defined two sets of differentially expressed genes that are up-or downregulated by OC2 perturbations, corresponding to up-and downregulated targets of OC2 in PC cells. The cellular processes represented by the up-and downregulated targets by OC2 were identified as the processes and pathways having P < 0.05 from DAVID v6.8 software (https://david.ncifcrf.gov/). Quantitative PCR. Total RNA was extracted (RNeasy Kit, Qiagen) and subjected to One-Step Real Time RT-PCR in a 7900HT Sequence Detection System with MultiScribe Reverse Transcriptase, RNase Inhibitor, TaqMan Gene Expression Master Mix (Applied Biosystems) and the TaqMan probes for ONECUT2 (Hs00191477_m1), AR (Hs00171172_m1), PSA (Hs02576345_m1), KLK2 (Hs01091576_m1), EHF (Hs00171917_m1), FOXA1 (Hs04187555_m1), NSE (Hs00157360_m1), CHGA (Hs00900370_m1), SYP (Hs00300531_m1), NFASC (Hs00391791_m1), TUBB2B (Hs00603550_g1), LHX2 (Hs00180351_m1), CAV2 (Hs00184597_m1), TGFB1 (Hs00998133_m1), MTSS1 (Hs00207341_m1), RET (Hs01120030_m1), PEG10 (Hs00248288_s1), EGFR (Hs01076090_m1), BASP1 (Hs00932356_s1), and NAT1 (Hs00265080_s1). Data were analyzed using the 2 −ΔΔCT method. ACTB and GAPDH TaqMan probes (Hs01060665_g1 and Hs02758991_g1, respectively) were used for normalization.
ChIP-qPCR and ChIP-seq. ChIP-qPCR and ChIP-seq experiments were performed with the ChIP-IT High Sensitivity Kit (Active Motif). Briefly, 80% confluent 22Rv1, LNCaP, or C4-2 cells were crosslinked with 1% formaldehyde at room temperature for 10 min. Chromatin was sonicated to 100-500 bp in a Bioruptor UCD-200 (Diagenode) and incubated overnight with 4 μ g of antibody (anti-OC2 HPA057058, Sigma; anti-REST 17-10456, EMD Millipore; anti-AR
Methods
Identification of key TFs. To identify key transcriptional regulators that drive PC progression, we performed a master regulator analysis based on a GSEA procedure. A compendium of TF and TF-target gene interaction information was collected from databases of genome-wide ChIP data in human (ChIPBase (http://rna.sysu. edu.cn/chipbase/), Amadeus (http://acgt.cs.tau.ac.il/amadeus/), and hmChIP (http://jilab.biostat.jhsph.edu/database/cgi-bin/hmChIP.pl)) and curated databases containing genes that share a TF-binding site (ChEA (http://amp.pharm.mssm. edu/Enrichr/geneSetLibrary?mode=text&libraryName=ChEA_2016), TRED (http://rulai.cshl.edu/cgi-bin/TRED/tred.cgi?process= home), and MSigDB (http://software.broadinstitute.org/gsea/msigdb)). To reflect context-dependent TF-target interactions in mCRPC, we selected interactions with significant correlation between TF and target genes on the basis of Spearman's rank correlation coefficient in 260 mCRPC transcriptome profiles. TF-target enrichment score (ES) was calculated using a Kolmogorov-Smirnov running sum statistic for each TF. We randomly permutated the sample labels and repeated ES calculation 10,000 times to compute the ES null distribution. Statistical significance of the ES was computed by comparing the observed ES with the ES null distribution. Normalized ES was computed by dividing the observed ES by the average of values > 0 from the ES null. A total of 31 TFs were selected on the basis of their high expression and significant enrichment of their target genes in the mCRPC cohort.
Construction of the network model. To construct a network model of TFs operating in mCRPC, we used the ten TFs with the largest number of leading edge subsets in the target genes. Interactions between the top ten TFs were initially assigned by the protein-protein interaction information from the STRING database (http://string-db.org/). We then estimated the strength of the interactions among the ten TFs by quantifying the expression concordance using the chi-squared test. The TF network model was reconstructed and visualized using Cytoscape software (http://cytoscape.org/), along with the TF expression in mCRPC, significance of their target gene regulation, and interaction strength between TFs.
Clinical outcome analysis. We studied the relationships between the OC2 expression and biochemical recurrence-free survival, metastasis-free survival, overall survival, and relapse-free survival in cancer types shown in Fig. 5g and Supplementary Figs. 5d and 7a. SurvExpress (http://bioinformatica.mty.itesm. mx:8080/Biomatec/SurvivaX.jsp) and PROGgeneV2 (http://watson.compbio. iupui.edu/chirayu/proggene/database/?url= proggene) tools were used to perform Kaplan-Meier analysis and Cox proportional hazard regression. OC2 expression and survival outcomes were correlated to assess significant associations. Samples were stratified by OC2 expression level at median value of all the samples in each cohort. 'Breast cancer 10 cohorts' indicates the breast metabase build from the SurvExpress database, which merges ten breast cancer cohorts generated by the same Affymetrix microarray platform. For every comparison, a corresponding P < 0.05 was considered significant.
Correlating OC2 expression and neural/NE tumor derivation in human cancer cell lines. Normalized OC2 mRNA expression intensities across 1,063 cancer cell lines were downloaded from the CCLE data portal (http://www.broadinstitute.org/ ccle/home). The Kolmogorov-Smirnov running sum statistic was applied to test whether high expression of OC2 is correlated with neural/NE tumor derivation. The 85 neural/NE cancer cell lines were identified using the annotation from the CCLE data portal, the IGRhCellID database, and the literature [27] [28] [29] [30] . A permutation test strategy was used to determine the statistical significance of a particular Kolmogorov-Smirnov statistic. The gene expression data were randomly shuffled 10,000 times to compute the empirical P value.
Prostate cell lines culture. Prostate cancer cell lines were obtained from the American Type Culture Collection. LNCaP, C4-2, and 22Rv1 were grown in RPMI-1640 media (Gibco) supplemented with 10% FBS and penicillin/ streptomycin. PC3 and DU145 were maintained in DMEM media (Gibco) supplemented with 10% FBS and penicillin/streptomycin. RWPE-1 were grown in keratinocyte serum-free medium (Gibco) supplemented with 0.05 mg ml −1 bovine pituitary extract and 5 ng ml −1 human recombinant epidermal growth factor. All cell lines tested negative for mycoplasma contamination.
Antibodies. Anti-OC2 HPA057058, rabbit, polyclonal (Sigma, lot no. R78318) was used for the ChIP-seq and ChIP-qPCR experiments (4 μ g per 30 μ g of chromatin); anti-OC2 21916-1-AP, rabbit, polyclonal (Proteintech, lot no. 00016559) was used for western blot (1:1,000); anti-OC2 ab28466, rabbit, polyclonal (Abcam) (1:400) and anti-OC2 LS-C499462 (LSBio, lot no. 118218) (1:200) were used for the immunohistochemistry (IHC) and IF studies; anti-AR N-20, rabbit, polyclonal (Santa Cruz, lot no. I1014) was used for ChIP-qPCR (4 μ g per 30 μ g of chromatin), coimmunoprecipitation (5 μ g per 500 μ g of protein), and western blot (1:500), anti-AR, clone D6F11, rabbit, monoclonal (Cell Signaling, no. 5153) was used for IHC (1:500); anti-PEG10 HPA051038, rabbit, polyclonal (Sigma) was used for IHC (1:500); anti-REST 17-10456, rabbit, polyclonal (EMD Millipore, lot no. 2665779) was used for western blot (1:1,000) and ChIP-qPCR (4 μ g per 30 μ g of chromatin) .
Luciferase assays. For the PSA promoter assay, the pGL3 vector containing the androgen-responsive 548-bp PSA promoter region (− 541 to + 7) preceded by 1450 bp of the PSA enhancer region (− 5322 to − 3873) (PSA-luc; provided by G. Coetzee, University of Southern California) was used. LNCaP or 22Rv1 cells were cotransfected with this luciferase construct, the OC2 overexpression vector or empty vector and the pRL-SV40 vector (Promega) with Lipofectamine 2000. Six hours after transfection cells were washed, maintained overnight in phenol-free RPMI supplemented with 10% charcoal-stripped FBS (Gibco), and treated for 24 h with 10 nM DHT (Sigma). Luciferase activity was measured using the Dual-Luciferase Assay System (Promega).
Animal studies. All experimental protocols and procedures were approved by the Institutional Animal Care and Use Committee at Cedars-Sinai Medical Center. All relevant ethical regulations, standards, and norms were rigorously adhered to. Male CrTac:NCr-Foxn1 nu nude mice and C.B-Igh− 1b/GbmsTac-Prkdc scid -Lyst bg N7 SCID/Beige mice (4-5 weeks old) were purchased from Taconic and maintained under specific pathogen-free conditions. For the subcutaneous experiments, 750,000 cells were resuspended in a total volume of 50 μ L PBS containing Matrigel (1:1 vol/vol; BD Bioscience) and injected into the flanks of nude mice. Tumor volume was measured and calculated using the formula V = 1/2 × length × width 2 .
For the OC2 inhibitor treatment study with the CSRM617 compound, mice bearing 22Rv1 tumors with a mean volume of 200 mm 3 were randomly divided into vehicle control (2.5% DMSO in PBS) or compound CSRM617 (50 mg kg ) groups and subjected to intraperitoneal injection daily. For the metastasis experiments, luciferase-tagged 22Rv1 cells (1 × 10 6 cells) were injected intracardially into 6-to 8-week-old SCID/Beige mice. Bioluminescence imaging was performed weekly to monitor tumor metastasis using a Xenogen IVIS Spectrum Imaging System (PerkinElmer). At the end of the animal studies, tumor tissues were collected from euthanized mice and fixed with 4% formaldehyde for histological analysis. Supplementary Fig. 7d shows a representative image of OC2 staining with the anti-OC2 Abcam antibody in PC tissue. TMAs were: (i) a prostate cancer TMA from the Cedars-Sinai Biobank (Fig. 1e,f and Figs. 2a-c) ; (ii) TMA 83, consisting of mCRPC cases from the rapid autopsy program at the University of Washington 32 (Fig. 4d,e and Supplementary Fig. 4c) ; and (iii) LuCaP xenograft TMAs 78.1 and 89A from the University of Washington 33 ( Fig. 4f,g and Supplementary Fig. 4d ). Each core in the TMA 83, 78.1, and 89A was annotated for presence or absence of expression of synaptophysin (SYP) and AR using immunohistochemistry and microscopic evaluation. Before analysis of primary prostate cancers in the TMA from Cedars-Sinai, cancer and normal glands were manually outlined by a pathologist (B.S.K.). DAPI or cytokeratin was used to distinguish nuclear and cytoplasmic compartments in cancer cells. Intensity levels of OC2 were determined in the nucleus and cytoplasm of cancer cells by averaging staining intensities across all cancer cells in a TMA core. The background intensity in the stroma was subtracted in cases of primary prostate cancer. Wilcoxon ranksum test was used to calculate the significance of differences in staining intensities between groups (normal, G3, G4).
IHC and IF.
For workup and validation of OC2 antibodies, tissue sections of pancreas, gallbladder, and large-cell NE carcinoma were used. Each staining experiment was controlled by including a positive and negative control slide. Results were evaluated by comparison with positive and negative controls. Staining results in positive and negative controls were consistent across multiple staining experiments. The specificity of the OC2 antibodies (Abcam ab28466, LSBio LS-C499462, and Sigma HPA057058 used by the Human Protein Atlas Consortium) was confirmed by staining of consecutive tissue sections from the same block with all three antibodies. Staining patterns in prostate cancer, gallbladder, and largecell NE cancer were similar between the three antibodies (data not shown). Immunofluorescent detection of OC2 was carried out with the OPAL 4-color kit (PerkinElmer) or with the Ventana Discovery Cy5 reagent kit (Ventana Medical Systems). TMA slides were first blocked with 3% H 2 O 2 for 10 min, then treated with animal-free protein blocker (Vector Laboratories) for 15 min, and then incubated overnight at 4 °C with the anti-OC2 primary antibody diluted in antibody dilution buffer (Ventana Medical Systems). The next day, the TMA slide was incubated with EnVision + System -HRP-labeled polymer goat antirabbit secondary antibody (Dako) for 30 min at room temperature followed by incubation with OPAL-Cy3 fluorophore for 10 min or alternatively with the Cy5 labeling kit. For slides labeled with Cy5, the cytokeratin 8/18 antibody cocktail was used to identify the cytoplasm of cancer cells. Slides were stained with DAPI and covered by ProLong Gold antifade solution before coverslipping for imaging. The TMA slide was imaged and digitized using the TissueFAX fluorescent slide scanner (TissueGnostics).
For double IHC with AR and OC2 antibodies, slides were first stained with OC2 as described above, except that tyramide amplification was used together with ImmPACT DAB Peroxidase (HRP) and red alkaline phosphatase (Red AP) chromogens (Vector Laboratories). Slides were first stained for OC2. Next, the OC2 antibodies were denatured and stripped off the slide using the Biocare Decloaker with pH 6 citrate buffer. Slides were treated with antigen retrieval solution pH 8, blocked and incubated with anti-AR antibody (no. 5153, clone D6F11, Cell Signaling) at 1:500 dilution. After signal amplification and development of the red chromogen, slides were stained with hematoxylin and surfaced by a cover N-20, Santa Cruz; or IgG control). After RNase A and Proteinase K treatment, ChIP DNA was purified with the column system provided with the kit. For targeted ChIP, eluted DNA was used for qPCR with the specific primers listed in Supplementary at the UCLA Clinical Microarray Core, followed by direct sequencing using the Illumina HiSeq3000 system. Pipeline for OC2 and AR peak classification. ChIP-seq data were processed in accordance with the AQUAS transcription factor and histone ChIP-seq processing pipeline (https://www.encodeproject.org/chip-seq/). The 'optimal' peak set was used for downstream analysis. Briefly, relaxed (with very low significance threshold) peaks were called with SPP 46 , and then input to IDR, to control the irreproducible discovery rate to < 0.05. After mapping to hg38 with BWA 47 and removing duplicates, there were > 65 million high-quality reads for all ChIPseq replicates. We used SPP 48 to calculate the cross-correlation quality control metrics and MACS2 + IDR to obtain the rescue ratio and self-consistency ratio for each cell line. We then used the DiffBind package in R/Bioconductor to assess differential binding of OC2 and AR in genomic regions. Within DiffBind, we calculated the read counts from each of our samples in the union of the IDR-called peaks and proceeded to assess differential binding of the OC2 and AR within this set. Differential binding was assessed with DESeq2 at FDR < 0.05. Shared peaks were identified as those not found in differentially enriched regions, but with overlapping peaks. These regions were visualized with deepTools2 49 and placed in genomic context with the ChIPSeeker package 50 and analyzed for gene ontology with the DOSE package 51 . Motifs were identified using MEME-Chip 52 within each peak set. Anti-AR, Anti-H3K4me1, and Anti-H3K27ac datasets from 22Rv1 cells were obtained from GEO (GSE85558). The ChIP-seq data were deposited into the GEO database (GSE97551).
Coimmunoprecipitation. These experiments were performed as previously described 53 . Briefly, LNCaP were seeded and, after 48 h in charcoal-stripped medium, cells were treated with 10 nM DHT or vehicle (100% ethanol) for an additional 24 h. Nuclear protein extracts were precleared and incubated with an AR antibody (N-20, rabbit, polyclonal; Santa Cruz, Lot no. I1014) at 4 °C overnight. AR-binding proteins were next precipitated with agarose beads and subjected to western blot.
Western blot analysis. Cell lysates were separated on 4-20% SDS-PAGE (Bio-Rad Laboratories) and transferred to nitrocellulose or PVDF membranes. The membranes were blocked with 5% nonfat dry milk and subsequently incubated with the pertinent primary antibody overnight. Membranes were subsequently washed with PBST (0.1% Tween-20) and incubated with an HRPconjugated secondary antibody (GE Healthcare BioSciences). After washing with PBST, the protein bands were detected by chemiluminescence (ThermoFisher Scientific). Entire blots are shown in Supplementary Figs. 8 and 9 .
Proliferation assays. To assay viability, cells were plated at a density of 1,000 cells per well in triplicate in a 96-well plate. Twenty-four hours after, cells were collected at time 0 h (T0) using a luminometric assay (CellTiter-Glo Luminescent Cell Viability Assay, Promega) and subsequently collected daily for 6 consecutive days. Cell viability was also assayed by crystal violet staining. Briefly, cells (150,000 cells per well in six-well plates) were seeded and transduced as indicated above. Cells were then fixed in 4% formaldehyde, washed, and subsequently stained with 0.1% crystal violet. Quantitation was performed by extracting the crystal violet dye with 10% acetic acid and measuring the absorbance at 590 nm on a SpectraMax M2 Microplate reader (Molecular Devices). The anchorageindependent growth of tumor cells was assayed by their ability to form colonies in agar plates. Soft agar assays were performed in triplicate in six-well plates. Ten-thousand cells per well were seeded in RPMI containing 0.4% low-melting agarose on bottom agar containing 0.7% low-melting agarose in RPMI medium. After 15 days, colonies were stained with iodonitrotetrazolium chloride and counted. Finally, for the colony assay, 1,000 cells were plated in six-well plates, and after 24 h cells were treated with vehicle (1% DMSO) or compound CSRM617 at 10, 20, and 40 µ M. Two weeks later, cells were fixed with 4% paraformaldehyde for 10 min at room temperature, and then stained with crystal violet for 15 min. Wells were scanned and the total area occupied by the colonies was quantified by ImageJ. 50 . Cells were plated at a density of 1,000 cells per well, in triplicate, in a 96-well plate. The next day, T0 readings were collected and cells were exposed to compound CSRM617 or vehicle (1% DMSO) at twofold concentration ranging from 100 μ M to 0.2 μ M. Viability was measured 48 h posttreatment using CellTiter-Glo Luminescent Cell Viability Assay (Promega). Dose-response curves and IC 50 values were generated using GraphPad Prism version 6 Software.
Dose-response curves and IC
was expressed at 18 °C overnight in Terrific Broth. Further purification was performed by Ni-NTA affinity chromatography using a HisTrap FF Crude column (GE Healthcare Life Sciences) and size-exclusion chromatography using a Superdex 200 increase 10/300 GL column (GE Healthcare Life Sciences) to yield > 95% pure protein.
Statistics and reproducibility. Statistically significant data for in vitro and in vivo assays were assessed by unpaired two-tailed Student's t-test or Wilcoxon two-tailed rank-sum test, unless otherwise noted. Tests for difference in the case of more than two groups were performed using one-way ANOVA where applicable using the Dunnett's post hoc test, unless otherwise indicated. Friedman's test was performed to compute significance of time-dependent changes by treatment. A permutation test strategy was used to determine the significance of overlap between OC2 target genes, where OC2 binds gene promoters, and total TF genes across the entire human genome. A total of 10,000 randomly selected genes were used to compute the empirical P value of the overlapping genes. We used GraphPad Prism (Version 6), MATLAB package including the Statistics toolbox (Mathworks), and the R package (v.3.1, http://www.r-project.org/) for all statistical tests. Network visualization was implemented using Cytoscape (v.3.4, http://www.cytoscape.org/) with enhancedGraphics application.
slip. Digital images of fields of view were captured by the Vectra-II slide scanner (PerkinElmer). Cancer areas in digital images of individual TMA cores were annotated by a pathologist (B.S.K). Nuclear outlines were determined on the basis of hematoxylin staining. AR and OC2 intensities in nuclear areas were measured. Intensity values of AR and OC2 were log 2 -transformed. An unsupervised hierarchical clustering of cells was performed based on AR and OC2 intensity values using Euclidean distance and complete linkage methods.
To measure expression of PEG10, tissues on glass slides were stained with the PEG10 antibody (Sigma HPA051038). Slides underwent heat retrieval with CC1 buffer (Ventana) for 40 min and 3% H 2 O 2 for 10 min. After blocking nonspecific binding with animal-free protein blocker for 15 min and with avidin/ biotin block for 5 min, slides were incubated with the PEG10 antibody at 1:1,000 dilution for 32 min at 37 o C. The antibody signal was amplified as described above with tyramide, and antibody binding was visualized using the ImmPACT DAB Peroxidase (HRP) (Vector) substrate kit. Slides were scanned on the Aperio Slide Scanner (Leica Biosystems), and the average staining intensity was determined using the software of the instrument (Aperio ImageScope).
Computer model of OC2 and drug discovery. 3D structure of human ONECUT2 (Uniprot: O95948) is not available and hence a structural model was built using homology modeling. OC2 consists of two DNA-binding domains, a CUT domain and a homeodomain (HOX) near the C terminus. Given the high sequence homology (90%) between rat and human OC1/Oc1 and OC2/Oc2, the homeodomain from the structure of rat Oc1 (PDB code: 2D5V) 54 was identified as a suitable structural template for inhibitor design. An initial structural model for human OC2 homeobox domain was subsequently generated using SWISS-MODEL 55, 56 . Prime module in Schrodinger (Schrodinger, Inc.) was additionally used to find an optimal conformation of the missing residues in the crystal structure. The final structural model was obtained after a cycle of minimization followed by a short 1.2-ns molecular simulation. Putative binding site of small molecules was identified with site score 0.569 9 (Dscore 0.398). Subsequently, the model was subjected to an extended molecular simulation (2.4 ns) with and without DNA. Models were averaged over 0.5 ns, and the sitemap score was reevaluated for each ensemble. Two models with site score 0.9 were used for virtual screening using Glide with extra precision mode. For virtual screening chemicals from Hit2Lead (Chembridge Corporation) were prepared using ligprep and used to identify hits. Figures were produced using Maestro 57 and PyMol (The PyMOL Molecular Graphics System, Version 1.8.2015) . Using the 3D model of OC2-HOX domain, we conducted a virtual screen of a chemical library consisting of 500,0000 small molecules (Chembridge). Stereochemistry of CSRM617 was not considered because it was not custom synthesized and therefore the preparations we used were a racemic mixture. Surface plasmon resonance-binding studies. To measure binding features of CSRM617, the OC2-HOX domain was recombinantly produced. The purified OC2-HOX domain protein was first verified using a DNA probe corresponding to the experimentally determined OC2-binding motif in the PEG10 promoter (F, 5′ -TAGATCGATTTGCA-3′ and R, 5′ -TGCAAATCGATCTA-3′ ). Briefly, 5 ng biotinylated dsDNA PEG10 probe was immobilized on a BioCap sensor chip (Pall ForteBio) in PBST buffer (pH 6.4) to a 300 response unit. OC2-HOX was analyzed at 62.5 nM concentration. Next, binding of CSRM617 was measured. Briefly, 5 μ g ml −1 purified His-tag OC2-HOX binding domain was immobilized on a HisCap chip (Pall ForteBio) to 20,000 response unit in PBST buffer (pH 6.4). CSRM617 was analyzed at serial doubling concentrations maximized at 100 μ M. The sensorgram was fit using a 2:2 model (that is, to a simple two-site binding model) using QDAT (SensiQ, Inc.) and to calculate K D .
SPR competition assay.
To examine whether CSRM617 can block DNA binding to OC2-HOX, biotinylated dsDNA containing the PEG10 motif described above was immobilized on BioCap sensor chip in PBST buffer containing 5% DMSO (pH 6.4) to a response unit of 300. OC2-HOX binding to the DNA was analyzed at two different protein concentrations, 250 nM (blue) and 125 nM (red), in the absence or presence of 100 μ M CSRM617.
OC2-HOX protein purification. Recombinant OC2-HOX domain (L330-W485) of OC2 was produced using a bacterial expression system. Briefly, OC2-HOX was subcloned into a pET-His6-TEV_LIC vector (1B, Addgene, plasmid no. 29653) to include an N-terminal His-tag. The recombinant plasmid was transformed into Rosetta (DE3) competent cells (Novagen) and OC2-HOX 1 nature research | reporting summary The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
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Data collection
The gene expression data collection for the DISC cohort can be found in www.thepcta.org. The source code of the PCTA is at https:// github.com/swiri021/PCTA_web_application/archive/master.zip
Data analysis
We used the GraphPad Prism (Version 6), the MATLAB package including the Statistics toolbox (Mathworks, Natick, MA, USA), the R package (v.3.1 http://www.r-project.org/) for all statistical tests. The following softwares were also used in this study: FlowJo v. 7.6.4., Matinspector (Genomatix), Cytoscape (v.3.4 http:// www.cytoscape.org/), SurvExpress (http://bioinformatica.mty.itesm.mx:8080 /Biomatec/SurvivaX.jsp), PROGgeneV2 (http:// watson.compbio.iupui.edu/chirayu /proggene/database/?url=proggene), The Cancer Cell Line Encyclopedia (CCLE) data portal (http:// www.broadinstitute.org/ccle/home), The ReMap 2018 (v.1.2; http://tagc.univ-mrs.fr/remap/index.php), IGRhCellID database (v.1.0; http://igrcid.ibms.sinica.edu.tw/cgi-bin/index.cgi), DAVID v6.8 software (https://david.ncifcrf.gov/), and The Molecular Signature Database (MSigDB) (v.6.5; http://software.broadinstitute.org/gsea/msigdb/index.jsp).
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Sample size
To test significance of transcription factors (TFs) in metastatic castration-resistant prostate cancer (CRPC), we assembled a large set of transcriptome profiles from 2,115 prostate cancer specimens. In order to reflect context dependent TF-target interactions in mCRPC, we selected interactions with significant correlation between TF and target genes based on Spearman's rank correlation coefficient in 260 mCRPC transcriptome profiles. This is expected to confer > 99% power to detect a correlation coefficient of >0.5, based on a significance level=0.05. TF-target enrichment score (ES) was calculated using a Kolmogorov-Smirnov running sum statistic for each TF. Significance was computed using a null distribution of the ES generated from random target gene sets by 100,000 permutations. Details are described in 'Identification of key TFs' in the Methods section.
Microarray experiments were performed with 3 independent samples per condition to identify differentially expressed genes (DEGs) and enriched gene sets to detect significantly altered genes between the condition using an integrated statistical method described in 'Gene expression microarrays' in the Methods section.
Significance levels of differential gene expression in various prostate cancer patient cohorts, including the Beltran et al. cohort and the prostate needle biopsy cohort were determined by Wilcoxon Rank-Sum test with more than 50 specimens. This has expected more than 80% power to detect > 50% difference between groups. All hypotheses were two-sided at 5% significance level.
For survival analysis, publicly available cancer cohort data were employed. Individual cohorts contain more than 50 samples on average.
In mouse experiments where 22Rv1 cells were subcutaneously injected after OC2 depletion, statistical significance of differences in tumor volume and weight between the groups was determined by unpaired two-tailed Student's t-test using 10 subjects per group. This is expected to confer > 80% power to detect a difference of more than 50%, based on a significance level=0.05.
In mouse experiments where 22Rv1 cells were intracardially injected after OC2 depletion, we determined significance level of difference in metastases by Wilcoxon two-tailed rank-sum test for 9 subjects per group. This accounts for > 80% power to detect a difference of more than 50%, based on significance level = 0.05.
In order to test the effect of CSRM617 treatment after subcutaneous injection of 22Rv1, we employed 11 tumors for the control group and 14 tumors for the experimental group. Significance was determined using unpaired two-tailed Student's t-test. This accounts for more than 80% power to detect a difference of > 50%, based on significance level = 0.05.
In order to test the effect of CSRM617 when treatment started two days after intracardiac injection of luciferase tagged 22Rv1 cells, we employed 7 mice per group and determined statistical significance by Friedman's two-tailed test. This accounts for > 80% power to detect a difference of more than 40%, based on significance level=0.05.
In order to test the effect of CSRM617 treatment in the context of established metastases after intracardiac injection of 22Rv1 cells, we employed 11 mice per group and determined statistical significance by two-way ANOVA. Multiple comparisons were performed using a Dunnett's test after ANOVA with 80% power at the 5% significance level.
Data exclusions No data were excluded from the analyses.
Replication
All attempts at replication were successful.
Randomization For the animal experiments with compound CSRM617, after injection of the cells, mice were randomized and treated with vehicle or CSRM617 as described in the manuscript.
Validation
The specificity of the OC2 antibodies ((Abcam ab28466, LS-Bio LS-C499462 and Sigma HPA057058 used by the Human Protein Atlas consortium) was confirmed by staining of consecutive tissue sections from the same block with all three antibodies. The remaining antibodies were validated by western blot (single band, correct molecular weight, expected response to physiological stimuli, overexpression and/or knockdown of the target).
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Cell line source(s)
American Type Culture Collection.
Authentication
Cell lines were authenticated by STR (short tandem repeat) analysis.
Mycoplasma contamination
All cell lines tested negative for mycoplasma contamination.
Commonly misidentified lines (See ICLAC register)
No commonly misidentify cell lines were used.
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Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research Laboratory animals 4-5 week-old male CrTac:NCr-Foxn1nu nude mice and C.B-Igh-1b/GbmsTac-Prkdcscid-Lystbg N7 SCID/Beige mice were purchased from Taconic
Wild animals
The study did not involve wild animals.
